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Background: Centralization of pancreatic surgery is currently called for owing to superior outcomes
in higher-volume centres. Conversely, organizational and patient concerns speak for a moderation in
centralization. Consensus on the optimal balance has not yet been reached. This observational study
presents a volume–outcome analysis of a complete national cohort in a health system with long-standing
centralization.
Methods: Data for all pancreatoduodenectomies in Norway in 2015 and 2016 were identified through a
national quality registry and completed through electronic patient journals. Hospitals were dichotomized
(high-volume (40 or more procedures/year) or medium–low-volume).
Results: Some 394 procedures were performed (201 in high-volume and 193 in medium–low-volume
units). Major postoperative complications occurred in 125 patients (31⋅7 per cent). A clinically relevant
postoperative pancreatic fistula occurred in 66 patients (16⋅8 per cent). Some 17 patients (4⋅3 per cent)
died within 90 days, and the failure-to-rescue rate was 13⋅6 per cent (17 of 125 patients). In multivariable
comparison with the high-volume centre, medium–low-volume units had similar overall complication
rates, lower 90-day mortality (odds ratio 0⋅24, 95 per cent c.i. 0⋅07 to 0⋅82) and no tendency for a higher
failure-to-rescue rate.
Conclusion: Centralization beyond medium volume will probably not improve on 90-day mortality or
failure-to-rescue rates after pancreatoduodenectomy.
Funding information
No funding
Paper accepted 20 July 2020
Published online 7 September 2020 in Wiley Online Library (www.bjsopen.com). DOI: 10.1002/bjs5.50342
Introduction
A volume–outcome effect on mortality after pancreato-
duodenectomy (PD) has been demonstrated repeatedly,
with lower short-term mortality rates in high-volume
centres1–5. The failure to prevent death in patients suffer-
ing from major postoperative morbidity (failure-to-rescue
(FTR)) has been proposed as a mechanism behind the
volume–outcome effect on mortality that is more impor-
tant than the occurrence of postoperative complications6,7.
Timely recognition and optimally sequenced treatment of
complications after PD is a complex matter and requires a
multidisciplinary approach8,9. A higher unit caseload nec-
essarily reflects greater experience in the handling of com-
plications. Academic teaching status of the treating hospital
has also been proposed to influence FTR7.
Covering a population of just 5⋅3 million inhabitants over
a vast geographical area, pancreatic surgery in Norway has
been restricted to only five hepatopancreatobiliary (HPB)
units for more than a decade10–12. All are academic teaching
hospitals with 24-h interventional radiology and endoscopy
services available, and highly resourced ICUs. Although
centralized, catchment areas vary substantially between
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the units, from high- to medium-volume combined HPB
and upper gastrointestinal units covering 0⋅5–1⋅0 million
inhabitants each, to a single very high-volume dedicated
HPB unit serving an uptake population of more than
2⋅6 million. The government funds the universal health-
care coverage, and there are no private institutions for
resectional surgery.
A previous nationwide analysis11 using administrative
data documented a low contemporary 90-day mortality rate
after PD in Norway, and negligible cross-regional patient
drift. There were similar regional population-based inci-
dences of the procedure and equal mortality rates among
patients treated at the respective units, but variation in
relaparotomy rates and use of vascular reconstruction was
demonstrated11. A significant proportion of relaparotomies
within 30 days (1 in 5) and deaths within 90 days (4 in 10)
occurred after first discharge from hospital11. The cen-
tralization of surgery within a single-payer health system
relies on patients being transferred back to general hos-
pitals for parts of the postoperative phase and follow-up.
Although still under the auspices of the operating (index)
unit, these transfers reduce the patients’ organizational
and geographical proximity to the index surgical unit in
the subacute recovery phase, where postoperative adverse
events may still develop. This is an inherent consequence
of centralization in all but the most densely populated
countries.
This study assessed overall and procedure-specific out-
comes in a complete national cohort of patients undergo-
ing PD, and investigated for a volume–outcome effect in a
country with longstanding centralization but a large varia-
tion in unit volume. The aim of the analysis was to examine
a potential benefit from further centralization.
Methods
All patients registered in the Norwegian Registry for Gas-
trointestinal and HPB Surgery (NoRGast) have given
written informed consent13. In addition, the project was
granted allowance from the Norwegian Directorate of
Health for additional access to electronic patient journal
(EPJ) data. Approval of alignment of the multicentre data
was given by the Data Protection Authority of Norway (ref-
erence number 17/33320-2).
Study design
This was an observational cohort study of complete nation-
wide data in a universal health coverage system. The
STROBE guidelines14 for reporting observational studies
were adhered to, where applicable.
Accrual of data
NoRGast is a procedure-driven national quality registry
with prospective gathering of core data for case mix and
postoperative complications13. All five Norwegian HPB
units contribute data to NoRGast. Data for all registered
pancreatoduodenectomies performed between January
2015 and December 2016 were retrieved from the NoR-
Gast database. Data from NoRGast were cross-checked
at a patient level by performing an identical search for
the same procedure codes in the local EPJs for each HPB
unit, and data for missing patients were included. In addi-
tion, procedure-specific variables and complications not
available in NoRGast (preoperative biliary drainage, dura-
tion of procedure, intraoperative haemorrhage, grade of
postoperative pancreatic fistula (POPF), grade of postpan-
createctomy haemorrhage (PPH) and histopathology data)
were registered manually from the EPJ for all patients by
a local HPB surgeon. Three of the four healthcare regions
have a shared regional EPJ, allowing direct access to
patient data for any transfer stays or readmissions outside
the index unit; this ensures data quality for complications
occurring after the index stay. In the one region where
regional EPJ access was not available, discharge reports
from transfer stays or readmissions were collected and
evaluated. Date of death is available automatically in the




Severe cardiac disease (New York Heart Association class
above 2 or severe arrhythmia) and pulmonary disease
(forced expiratory volume in 1 s less than 50 per cent and/or
vital capacity below 60 per cent) were defined in accordance
with the modified form of the Estimation of Physiologic
Ability and Surgical Stress (E-PASS) system15. Diabetes
mellitus was defined by preoperative use of any antidiabetic
medication, administered either subcutaneously or orally.
Procedure details and postoperative complications
Any complication graded as 3 or above in the Accordion
system16 was considered a major complication. Briefly,
Accordion grade 3 refers to percutaneous or endoscopic
reintervention with or without general anaesthesia; Accor-
dion 4 refers to relaparotomy or single-organ failure (SOF);
Accordion 5 refers to relaparotomy and SOF, or multi-
ple organ failure alone; and Accordion 6 refers to death.
POPF17, PPH18 and venous resection19 were scored in
accordance with proposed guidelines from the Interna-
tional Study Group of Pancreatic Surgery.
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Table 1 Patient demographics




(n = 193) Unit range# P††
Age (years)* 67⋅5 (60–73) 68 (61⋅5–74) 67 (58–72) 66–67⋅5 0⋅364‡‡
BMI (kg/m2)* 24⋅5 (21⋅9–26⋅9) 24⋅1 (21⋅7–26⋅7) 24⋅6 (22⋅0–27⋅1) 24⋅2–25⋅5 0⋅271‡‡
Albumin (g/l)* 40⋅0 (36⋅0–43⋅0) 40⋅0 (35⋅5–43⋅0) 40⋅0 (36⋅0–43⋅0) 36⋅0–43⋅0 0⋅584‡‡
Weight loss† n = 315 n = 149 n = 166
Any 231 (73⋅3) 117 (78⋅5) 114 (68⋅7) (62⋅5–71⋅7) 0⋅064
>5% 185 (58⋅7) 101 (67⋅8) 84 (50⋅6)
>10% 90 (28⋅6) 62 (41⋅6) 28 (16⋅9)
Diabetes mellitus‡ 68 (17⋅3) 36 (17⋅9) 32 (16⋅6) (6⋅3–22⋅6) 0⋅829
Neoadjuvant chemotherapy 22 (5⋅6) 11 (5⋅5) 11 (5⋅7) (0–12⋅9) 0⋅922
Severe pulmonary disease§ 15 (3⋅8) 3 (1⋅5) 12 (6⋅2) (0–18⋅8) 0⋅014
Severe cardiac disease¶ 23 (5⋅8) 11 (5⋅5) 12 (6⋅2) (0–11⋅3) 0⋅753
Preoperative drainage 150 (38⋅1) 88 (43⋅8) 62 (32⋅1) (25⋅8–37⋅1) 0⋅017
ERCP 134 (34⋅0) 88 (43⋅8) 46 (23⋅8) (17⋅8–31⋅3)
PTC 16 (4⋅1) 0 (0) 16 (8⋅3) (0–15⋅6)
ECOG score 0⋅083
0 288 (73⋅1) 157 (78⋅1) 131 (67⋅9) (62⋅2–71⋅4)
1 95 (24⋅1) 39 (19⋅4) 56 (29⋅0) (25⋅7–37⋅5)
>1 11 (2⋅8) 5 (2⋅5) 6 (3⋅1) (0–4⋅4)
ASA grade 0⋅487
I–II 216 (55⋅0) 106 (53⋅0) 110 (57⋅0) (46⋅8–75⋅0)
≥ III 177 (45⋅0) 94 (47⋅0) 83 (43⋅0) (25⋅0–53⋅2)
Histopathology (extracted specimens) n = 393 n = 201 n = 192** 0⋅072
Any malignancy 324 (82⋅4) 173 (86⋅1) 151 (78⋅6) (67⋅1–93⋅8)
PDAC 161 (41⋅0) 83 (41⋅3) 78 (40⋅6)
Common bile duct cancer 58 (14⋅8) 36 (17⋅9) 22 (11⋅5)
Duodenal cancer 36 (9⋅2) 25 (12⋅4) 11 (5⋅7)
Ampullary/papillary cancer 30 (7⋅6) 9 (4⋅5) 21 (10⋅9)
Other 39 (9⋅9) 20 (10⋅0) 19 (9⋅9)
Any benign disease 69 (17⋅6) 28 (13⋅9) 41 (21⋅4) (6⋅3–32⋅9)
IPMN without adenocarcinoma 25 (6⋅4) 5 (2⋅5) 20 (10⋅4)
Pancreatitis 11 (2⋅8) 9 (4⋅5) 2 (1⋅0)
Other 33 (8⋅4) 14 (7⋅0) 19 (9⋅9)
Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.). †Patient-reported weight loss in 6 months before surgery.
‡Defined by use of any antidiabetic medication, administered subcutaneously or orally. §Forced expiratory volume in 1 s less than 50 per cent or vital
capacity less than 60 per cent. ¶New York Heart Association class 3–4 or arrhythmia requiring mechanical support. #Within medium–low volume category.
**One patient died during surgery. ERCP, endoscopic retrograde cholangiopancreatography; PTC, percutaneous transhepatic cholangiography; ECOG,
Eastern Co-operative Oncology Group; PDAC, pancreatic ductal adenocarcinoma; IPMN, intraductal papillary mucinous neoplasm. ††χ2 test (high versus
medium–low volume, dichotomized), except ‡‡Kruskal–Wallis test.
Failure-to-rescue
FTR was defined as any death within 90 days in patients
with any major complication (Accordion grade 3 or above).
Deaths with no recorded preceding major complication
were included, in accordance with the original20 and
recommended21 definition.
Hospital volume
Hospital units were dichotomized according to procedure
volume, and defined as high volume for 40 or more pro-
cedures per year (1 unit) or as medium–low volume for
fewer than 40 procedures per year (4 units). Others3,5,6,22–24
have suggested this cut-off, and it allowed for meaningful
comparison within the Norwegian setting. Length of stay
was defined conventionally as the number of postoperative
nights spent at the hospital after the procedure, omitting
any transfer and/or readmission stays.
Primary outcomes
The primary outcomes of the study were incidence and
type of major postoperative complications, overall 90-day
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Table 2 Procedure characteristics




(n = 193) Unit range‡ (16–70) P§
Estimated blood loss (ml) (n = 352)* 350 (700–1200) 200 (100–500) 490 (300–490) 300–1165 <0⋅001¶
Duration of surgery (min) (n = 383)* 322 (262–386) 341 (283–418) 300 (240–300) 240–431 <0⋅001¶
Without VR 308⋅5 (252–359) 323 (274–373) 300 (240–343) 240–354 <0⋅001¶
With VR 420 (355–454) 420 (369–454) 393 (337–465) 240–431 0⋅415¶
Classical PD† 206 (52⋅3) 60 (29⋅9) 146 (75⋅6) (12⋅5–100) <0⋅001
Peroperative blood transfusion 76 of 391 (19⋅4) 38 of 198 (19⋅2) 38 (19⋅7) (10⋅0–35⋅5) 0⋅901
Any vascular resection 70 (17⋅8) 50 (24⋅9) 20 (10⋅4) (5⋅7–17⋅7) <0⋅001
Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.). †Classical pancreatoduodenectomy (PD) (Whipple procedure);
all others were pylorus-preserving pancreatoduodenectomies. ‡Within medium–low volume group; the lowest case volume was 16 and the highest was 70.
VR, vascular resection. §χ2 test (high versus medium–low volume, dichotomized), except ¶Kruskal–Wallis test.
Table 3 Short-term outcomes




(n = 193) Unit range† P‡
Any major complication 125 (31⋅7) 57 (28⋅4) 68 (35⋅2) (31⋅2–42⋅2) 0⋅143
Accordion 3 46 (11⋅7) 21 (10⋅4) 25 (13⋅0) 0⋅436¶
Accordion 4 51 (12⋅9) 22 (10⋅9) 29 (15⋅0)
Accordion 5 15 (3⋅8) 6 (3⋅0) 9 (4⋅7)
Accordion 6 (30-day mortality) 10 (2⋅5) 8 (4⋅0) 5 (2⋅6)
POPF n = 393 n = 201 n = 192
None or biochemical leak 327 (83⋅2) 180 (89⋅6) 147 (76⋅6) (71⋅4–83⋅6)
Grade B 41 (10⋅4) 13 (6⋅5) 28 (14⋅6) (6⋅3–17⋅1) <0⋅001#
Grade C 25 (6⋅4) 8 (4⋅0) 17 (8⋅9) (3⋅3–12⋅5)
PPH n = 393 n = 201 n = 192
None or grade A 349 (88⋅8) 177 (88⋅1) 172 (89⋅6) (85⋅7–100) 0⋅741#
Grade B 22 (5⋅6) 10 (5⋅0) 12 (6⋅3) (0–8⋅2)
Grade C 22 (5⋅6) 14 (7⋅0) 8 (4⋅2) (0–7⋅1)
Relaparotomy 71 (18⋅1) 32 (15⋅9) 39 (20⋅3) (8⋅2–28⋅6) 0⋅258
Haemorrhage 23 (5⋅9) 13 (6⋅5) 10 (5⋅2) 0⋅026¶
Pancreatic leak 17 (4⋅3) 5 (2⋅5) 12 (6⋅3)
Biliary leak 8 (2⋅0) 1 (0⋅5) 7 (3⋅6)
Wound dehiscence 4 (1⋅0) 4 (2⋅0) 0 (0)
Other 19 (4⋅8) 9 (4⋅5) 10 (5⋅2)
90-day mortality 17 (4⋅3) 11 (5⋅5) 6 (3⋅1) (0–6⋅3) 0⋅323
Length of stay at index hospital (days) (n = 391)* 9 (7–16) 7 (6–11) 14 (9–21) 7–18 <0⋅001§
No major complication* 8 (6–13) 7 (6–8) 13 (8–15) 7–15 <0⋅001§
Any major complication* 18 (11–29) 14 (10–30) 21 (13–28) 13–24 0⋅129§
Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.) with median unit range. †Within medium–low volume
group. POPF, postoperative pancreatic fistula; PPH, postpancreatectomy haemorrhage. ‡χ2 test (high versus median–low volume, dichotomized), except
§Kruskal–Wallis test; ¶univariable χ2 comparison of Accordion grade or reason for relaparotomy distribution; #univariable χ2 comparison of presence of
clinically relevant POPF or PPH grade B–C.
mortality, and 90-day mortality among patients with major
postoperative complications (FTR).
Statistical analysis
Crude demographics, procedure details, major compli-
cations and histopathology data are presented as median
(i.q.r.) values, or as absolute numbers with percent-
ages. Crude comparison across volume categories was
done using the χ2 test for categorical variables and the
Kruskal–Wallis (non-parametric) test for continuous
variables.
Multivariable logistic regression analyses of the postop-
erative outcomes any major complication, relaparotomy,
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Table 4 Multivariable analysis of predictors of postoperative complications*
Odds ratios
Any major complication Relaparotomy 90-day mortality CR POPF PPH grade B or C
Age (years)
<65 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
65–74 1⋅19 (0⋅73, 1⋅91) 1⋅20 (0⋅68, 2⋅51) 4⋅63 (0⋅87, 24⋅22) 1⋅24 (0⋅69, 2⋅25) 0⋅95 (0⋅47, 1⋅92)
≥75 0⋅60 (0⋅31, 1⋅16) 0⋅57 (0⋅24, 1⋅34) 7⋅66 (1⋅14, 51⋅44) 0⋅62 (0⋅26, 1⋅49) 0⋅58 (0⋅20, 1⋅69)
P 0⋅112 0⋅212 0⋅098 0⋅271 0⋅594
Sex
F 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
M 1⋅21 (0⋅78, 1⋅89) 1⋅23 (0⋅72, 2⋅09) 3⋅69 (1⋅05, 13⋅02) 0⋅97 (0⋅51, 1⋅85) 1⋅77 (0⋅91, 3⋅45)
P 0⋅393 0⋅452 0⋅042 0⋅934 0⋅092
Indication
Any malignancy 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
Benign disease 1⋅75 (0⋅92, 2⋅98) 0⋅82 (0⋅39, 1⋅87) 0⋅41 (0⋅04, 3⋅84) 1⋅96 (0⋅94, 3⋅44) 0⋅86 (0⋅33, 2⋅27)
P 0⋅087 0⋅602 0⋅438 0⋅098 0⋅767
Vascular resection
No 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
Yes 1⋅30 (0⋅72, 2⋅34) 1⋅62 (0⋅84, 2⋅81) 1⋅33 (0⋅30, 5⋅81) 0⋅72 (0⋅30, 1⋅71) 4⋅27 (2⋅20, 8⋅28)
P 0⋅381 0⋅149 0⋅709 0⋅456 <0⋅001
Preoperative biliary drainage
No 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
Yes 0⋅72 (0⋅45, 1⋅16) 0⋅79 (0⋅52, 1⋅64) 0⋅21 (0⋅05, 0⋅86) 0⋅50 (0⋅27, 0⋅92) 0⋅57 (0⋅28, 1⋅15)
P 0⋅178 0⋅781 0⋅030 0⋅025 0⋅117
Peroperative RBC transfusion
No 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
Yes 1⋅68 (0⋅99, 2⋅85) 2⋅12 (1⋅17, 3⋅82) 1⋅78 (0⋅49, 6⋅33) 1⋅28 (0⋅64, 2⋅57) 1⋅68 (0⋅81, 3⋅49)
P 0⋅053 0⋅013 0⋅376 0⋅481 0⋅164
Relaparotomy
No 1⋅00 (reference)
Yes 20⋅72 (6⋅03, 71⋅18)
P <0⋅001
Unit volume
High 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
Medium–low 1⋅28 (0⋅82, 1⋅98) 1⋅38 (0⋅82, 2⋅33) 0⋅24 (0⋅07, 0⋅82) 2⋅52 (1⋅43, 4⋅43) 1⋅10 (0⋅55, 2⋅19)
P 0⋅274 0⋅229 0⋅023 0⋅001 0⋅782
Values in parentheses are 95 per cent confidence intervals. *Other potential predictors evaluated in the multivariable logistic regression analysis, but not
found to be significant predictors were BMI, weight loss greater than 10 per cent, albumin, diabetes mellitus, neoadjuvant chemotherapy, severe pulmonary
disease, severe cardiac disease, Eastern Co-operative Oncology Group class above zero, ASA grade above II, duration of surgery and type of procedure.
CR POPF, clinically relevant postoperative pancreatic fistula; PPH, postpancreatectomy haemorrhage; RBC, red blood cell.
clinically relevant (CR) POPF and PPH grade B/C were
performed using a backwards stepwise approach, where
centre volume was included as a predictor. A similar mul-
tivariable model was built to evaluate the predictors of
death after major postoperative complications (FTR). The
regression models were assessed for significant interac-
tions and collinearity. Effect measures from multivariable
analyses are reported as odds ratios (ORs) with 95 per
cent confidence intervals. Level of significance for all final
analyses was set to P < 0⋅050.
IBM SPSS Statistics version 26.0 (IBM, Armonk New
York, USA) was used for all statistical analyses.
Results
A total of 394 patients in Norway had a PD (all open
resections) during the 2-year study period. Mean
annual procedure volume ranged from 101 PDs in the
high-volume centre to 35, 31, 23 and eight PDs respec-
tively (median 27) in the four medium–low-volume
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Table 5 Characteristics of 17 patients who died within 90 days of surgery






M 47 MV None CW, vein resection
type 1
PDAC (R1) Relaparotomy, POPF grade B,
PPH grade C
30 No
M 67 HV None PPPD Pancreatitis Sudden cardiac arrest POD 5 30 No
F 85 HV None PPPD PDAC (R1); extensive SMA
dissection
Diarrhoea, renal failure 30 Yes
M 68 HV None PPPD Duodenal adenocarcinoma Relaparotomy, PPH grade C 30 No
M 76 HV Cardiac
disease
CW Distal CC (R1) Relaparotomy (wound
dehiscence only)
30 No
M 76 MV DM PPPD Other malignancy (R0) Relaparotomy, POPF grade C,
PPH grade C
30 No
F 71 MV None CW Other malignancy (R0) Relaparotomy (wound
dehiscence only)
30 No
F 65 MV DM CW No specimen retrieved Peroperative death from
haemorrhage
30 No
M 69 LV None PPPD Distal CC (R0) Relaparotomy, POPF grade C 30 No
F 70 HV None CW, vein resection
type 3
Distal CC (R0) Relaparotomy, POPF grade C,
PPH grade C
30–90 No
F 71 HV None PPPD, vein
resection type 3
PDAC (R1) Relaparotomy, POPF grade C 30–90 Yes
M 63 HV None CW, vein resection
type 3
PDAC (R1) Infection after initiating
adjuvant chemotherapy
30–90 Yes




Pneumonia, prolonged DGE 30–90 Yes
M 74 HV DM CW Duodenal
adenocarcinoma (R1)
Relaparotomy, POPF grade C,
PPH grade C
30–90 No





M 74 MV None CW PDAC (R0) Relaparotomy, POPF grade C,
PPH grade C
30–90 No
M 71 HV None PPPD Distal CC (RO) Relaparotomy, POPF grade C 30 No
*International Study Group of Pancreatic Surgery classification of vein resection. MV, medium volume; CW, classical Whipple procedure; PDAC, pancre-
atic ductal adenocarcinoma; POPF, postoperative pancreatic fistula; PPH, postpancreatectomy haemorrhage; HV, high volume; PPPD, pylorus-preserving
pancreatoduodenectomy; POD, postoperative day; SMA, superior mesenteric artery; CC, cholangiocarcinoma; DM, diabetes mellitus; LV, low volume;
DGE, delayed gastric emptying.
units. Follow-up at 30 days (complications) and 90 days
(mortality) was complete (394, 100 per cent).
Patient demographics
Baseline patient data are presented in Table 1. The median
age was 67⋅5 (i.q.r. 60–73) years, and 187 (47⋅5 per cent)
of the patients were men. Of 393 extracted specimens
(1 intraoperative death with no retrieved specimen),
malignant disease was confirmed in 324 (82⋅4 per cent).
Pancreatic ductal adenocarcinoma (PDAC) was found
in 161 (49⋅7 per cent) of malignant specimens. Patients
treated in the high-volume centre had a significantly
higher rate of preoperative biliary drainage than those in
the medium–low-volume units (88 of 201 (43⋅8 per cent)
versus 62 of 193 (32⋅1 per cent) respectively; P = 0⋅017),
and a lower rate of severe pulmonary disease (3 of 201
(1⋅5 per cent) versus 12 of 193 (6⋅2 per cent); P = 0⋅014).
There were no other significant differences in patient
characteristics between patients treated in the high- and
medium–low-volume units, including no difference in
proportions of specimens with malignant versus benign
disease.
Procedure characteristics
Procedure characteristics are presented in Table 2. Con-
comitant vascular resection (vein or artery) was done in 70
(17⋅8 per cent) of the operations, and specifically in 54 of
161 (33⋅5 per cent) of resections for PDAC. Patients treated
in the high-volume centre had significantly lower estimated
blood loss and longer duration of surgery for all procedures
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High-volume centre (n= 201)
Medium–low-volume units combined (n= 193)
Medium-volume unit
Low-volume unit
a Postoperative complications (Accordion grade 3–6); b 90-day mortality; c failure-to-rescue. Multivariable analysis with high volume as reference (odds
ratio (OR) 1⋅00): a OR 1⋅28 (95 per cent c.i. 0⋅82 to 1⋅98), P = 0⋅274; b OR 0⋅24 (0⋅07 to 0⋅82), P = 0⋅023; c OR 0⋅49 (0⋅26 to 1⋅63), P = 0⋅243.
and for PDs without concomitant vascular resection, a
lower rate of classical PD (versus pylorus-preserving PD)
and a higher rate of any vascular resection. Most arterial
resections were performed in the high-volume centre (14
of 16); none of these 16 patients died within 90 days.
Postoperative complications
Crude rates of postoperative complications and univariable
comparison between volume categories are presented in
Table 3. Major complications occurred in 125 patients (31⋅7
per cent). Results from multivariable analyses are presented
in Table 4. When analysing centre volume category as a
predictor of postoperative outcomes, medium–low volume
was a predictor of lower mortality within 90 days (OR 0⋅24,
95 per cent c.i. 0⋅07 to 0⋅82) but of a higher rate of CR
POPF (OR 2⋅52, 1⋅43 to 4⋅43). Medium–low-volume unit
did not independently predict occurrence of any major
complication, relaparotomy or PPH grade B/C. Impor-
tantly, variation in the use of vascular resection between
the volume categories was adjusted for.
Failure-to-rescue
Detailed patient data for all patients who died within
90 days are shown in Table 5. All but four of the patients
who died within 90 days experienced at least one major
surgical complication within 30 days: CR POPF (8 of 17),
PPH grade B/C (6 of 17) and relaparotomy (12 of 17). The
rate of FTR after any major complication was 13⋅6 per cent
(17 of 125). The mortality rate after any relaparotomy and
PPH grade B/C was 12 of 71 (17 per cent) and 7 of 44 (16
per cent). Overall mortality after CR POPF was eight of
66 (12 per cent), with separate mortality rates after POPF
grade B and C of one of 41 (2 per cent) and seven of 25 (28
per cent) respectively.
The FTR rate in the high-volume centre was 11 of 57
(19 per cent), compared with six of 68 (9 per cent) in
medium–low-volume units (Fig. 1). In multivariable analy-
sis assessing the same predictors as for postoperative com-
plications (Table 4), medium–low unit volume was not an
independent predictor of higher FTR (OR 0⋅49, 95 per
cent c.i. 0⋅26 to 1⋅63; P = 0⋅243).
Discussion
These data indicate that results similar to those in
high-volume expert centres may be obtained within a
single-payer PD service practising a moderate degree
of centralization. The sole high-volume centre had out-
comes on a par with those from internationally renowned
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high-volume centres24, but, importantly, so had the three
medium-volume centres with 20–40 procedures per year.
This suggests that a balance between beneficial short-term
clinical outcomes and organizational concerns may have
been obtained with this caseload.
The national outcomes in terms of rates of any major
complication, POPF, PPH and FTR are comparable to the
results and benchmarks cut-off values established from an
international cohort of 23 high-volume expert centres25.
Of note, whereas their benchmark values25 were based on a
subset of low-risk patients, excluding more than 50 per cent
of their total patient cohort, the present study included 100
per cent of patients operated on across Norway during the
study period (a true population-based cohort).
As shown previously11, national 30- and 90-day mortality
rates were low in comparison with contemporary cohorts
from Germany, France and the USA, and in line with rates
reported from Sweden and the Netherlands1,2,26–28. Rates
of any major complication, CR POPF and PPH grade
C were equal to coeval cohorts from the USA, Nether-
lands and Germany22,29,30. The relaparotomy rate in the
present cohort (18⋅1 per cent) was similar to, or some-
what higher than, that reported from other studies22,30,31.
Compared with similar population-based cohorts29,30, the
median operating time of 322 min was short and median
estimated blood loss (350 ml) was low.
The national rate of FTR after PD of 13⋅6 per cent
in the present cohort is in line with recent rates of 9
per cent reported from the US American College of Sur-
geons National Surgical Quality Improvement Program
database32 and 14⋅3 per cent in the Dutch Pancreatic Can-
cer Audit6. Importantly, the existing diversity in defini-
tions of major postoperative morbidity used to calculate
FTR rates hampers a direct comparison between studies.
A Dutch study33 of the management of POPF used a def-
inition similar to that employed in the present study, and
reported an in-hospital mortality rate after CR POPF of
17⋅8 per cent. In comparison, the present cohort demon-
strated a 90-day mortality rate after CR POPF of 12
per cent.
The national mortality rate after PD achieved within
the current organizational model in Norway is very low,
and the improvement potential in terms of short-term
mortality is not obvious. A root-cause analysis of mor-
tality within 90 days after major pancreatectomy by
Vollmer and colleagues34 found pancreatic fistula or other
surgery-related cause as the main reason for death in 13⋅8
and 26⋅6 per cent respectively, and the relaparotomy rate
among the patients who died was 35⋅3 per cent. In contrast,
the present cohort demonstrated that 14 of 17 patients who
died within 90 days experienced surgical complications,
and almost three in four had a relaparotomy within 30 days
of the index operation. Despite the already reassuring
national mortality rate, a potential for further decline may
lie in a future focus on lowering the incidence, and timely
and optimal handling, of surgical complications.
The medium–low-volume units had similar outcomes
to those in the high-volume centre. This stands in con-
trast to a perceived more linear volume–outcome effect,
as suggested in several earlier reports1,5,31. Moreover, and
supporting the present observations, other reports6,24,35
have also failed to show superior outcomes in high-volume
units in comparison with medium-volume units. When
assessing the literature of the volume–outcome relation-
ship, one must be aware of the various definitions used for
volume categories. Although the present analysis used 40
procedures a year as the cut-off for high volume, as have
others5,6,22, several other publications4,36 have defined high
volume as more than 20 procedures a year. According to
this definition, the vast majority (95⋅9 per cent) of the pro-
cedures constituting the present cohort were performed
in high-volume units, and hence the broadly accepted
volume–outcome relationship would serve as an explana-
tory factor for the beneficial results. The single low-volume
unit represents an outlier in the medium–low-volume
category. It was included in the analyses in order to
present a complete national cohort. The absolute num-
bers of resections performed in this unit (16 over 2 years)
did not allow for statistical comparison in a separate
low-volume category, but the degree of divergence in out-
comes (Fig. 1) was deemed too low to skew the results in
the medium–low-volume category combined.
The equity in key short-term outcome metrics observed
across the large span in unit volume in the present cohort
raises the question of whether other organizational fac-
tors can compensate for a moderate case load (20–40 pro-
cedures a year). A ceiling effect of the volume–outcome
benefits may be reached within this interval, and several
mechanisms may contribute to this. All five units perform-
ing pancreatic resections are academic centres, which have
been shown previously to contribute more to lower mor-
tality and FTR rates than unit caseload itself7,37,38. Fur-
ther, all four medium–low-volume units annually perform
other HPB and upper gastrointestinal resections in num-
bers at least fourfold of their caseload for PD. This fre-
quent exposure to anatomically related surgery has been
proposed to contribute to improved outcomes after PD,
and even to compensate for a lower volume of pancre-
atic surgery39. The lower length of stay in the index unit
(before transfer) in the high-volume centre, combined
with higher 90-day mortality and (although statistically
non-significant) almost twofold higher FTR rate, is also
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of interest. It raises the question of whether follow-up in
geographical and organizational vicinity to the index unit
and operating surgeon, which is to a larger extent practised
by the medium–low-volume units, is beneficial for optimal
and timely recognition and handling of complications. Of
note, the higher mortality rate in the high-volume centre
found in the present cohort must be interpreted with cau-
tion, as the authors demonstrated previously11, in a larger
and partly overlapping cohort, that there was no difference
in 90- and 180-day mortality between the regional health
authorities in Norway.
From the patient’s perspective, clinical outcomes after
surgery are paramount, and outscore reasonable increases
in longer travel distances to the treating hospital unit40–42.
However, continuity in care during preoperative workup,
surgery and long-term postoperative follow-up, as well as
accessibility to specialized healthcare providers for contact
and information, also weighs heavily41, and is perhaps
easier to obtain within an organizational model with a
moderate level of centralization.
Several limitations deserve to be acknowledged. First, the
present cohort is not large and, owing to a small abso-
lute number of rare events, suffers from the risk of being
underpowered. Second, as the analyses classified only one
unit in the high-volume category, transferability to other
high-volume units in general is weakened. Data on gland
texture and duct diameter were not available, and a fistula
risk score could not be included as a co-variable. However,
as shown previously11, both the identical population-based
incidence of PD across the nation and the negligible
regional patient drift, together with the similar propor-
tions of malignant versus benign specimens found in the two
unit-volume categories, make a large disparity in case mix
and fistula risk score highly unlikely.
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